Comparative Pharmacology
Head-to-head clinical analysis: LANTUS SOLOSTAR versus TOUJEO MAX SOLOSTAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LANTUS SOLOSTAR versus TOUJEO MAX SOLOSTAR.
LANTUS SOLOSTAR vs TOUJEO MAX SOLOSTAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin glargine is a recombinant human insulin analog with prolonged duration of action. It binds to insulin receptors, activating downstream signaling pathways including PI3K/Akt, leading to increased glucose uptake in peripheral tissues, inhibition of hepatic gluconeogenesis, and promotion of glycogenesis and lipogenesis. The long-acting profile is due to precipitation at subcutaneous injection site with slow absorption.
Insulin glargine is a recombinant human insulin analog that exhibits prolonged duration of action. It binds to the insulin receptor, activating downstream signaling pathways to promote glucose uptake in peripheral tissues, inhibit hepatic gluconeogenesis, and suppress lipolysis and proteolysis.
Injection, subcutaneous: initial: 0.2 units/kg once daily, typical maintenance: 0.5-1 unit/kg once daily, max: 80 units/day.
Subcutaneous injection once daily at the same time every day. Starting dose for patients with type 2 diabetes: 0.2 units/kg or 10 units once daily, titrated based on fasting plasma glucose. Maximum dose per injection: 160 units (2 mL) or 300 units (3 mL) depending on prefilled pen.
None Documented
None Documented
Terminal elimination half-life is 12.5 hours (range 10-18 hours) after subcutaneous administration due to prolonged absorption from the injection site, reflecting the duration of action.
Terminal elimination half-life of 19 hours (range 16-21 h) in steady state, reflecting prolonged insulin glargine absorption from the subcutaneous depot.
Renal (minimal, intact drug not excreted), metabolized to inactive metabolites excreted renally and fecally; unchanged insulin glargine does not undergo significant renal excretion, degradation products excreted renally (~30%) and fecally (~70%).
Degraded by insulin-degrading enzyme; minimal renal excretion (<1% unchanged). Biliary/fecal elimination accounts for the remainder.
Category C
Category C
Long-Acting Insulin
Long-Acting Insulin